ストックスクリーナーアプリを入手
109.62
0.02%
0.24
Nuvalent Inc (NUVL) 最新ニュース
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - PR Newswire
Nuvalent (NUVL) Receives a New Rating from Truist Financial - The Globe and Mail
Nuvalent: Deerfield funds sell $70.8m in NUVL stock By Investing.com - Investing.com Nigeria
Nuvalent: Deerfield funds sell $70.8m in NUVL stock - Investing.com India
Nuvalent closes $500 million public offering of common stock By Investing.com - Investing.com South Africa
Nuvalent Closes Public Offering of Common Shares - MarketScreener
Nuvalent (NASDAQ: NUVL) closes $500M stock offering; 4,950,496 shares sold in public deal - Stock Titan
FDA accepts NDA for Nuvalent's zidesamtinib for non-small cell lung cancer - MSN
J.P. Morgan Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Four companies raise nearly $950M in follow-ons: Public Equity Report - biocentury.com
Nuvalent Announces $500M Stock Offering Pricing - The Globe and Mail
Biotech Stock Gets Booted in Latest Fund Update - AOL.com
Will Nuvalent Inc. stock keep outperforming rivalsJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Why analysts upgrade Nuvalent Inc. stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - newser.com
Sidley Represents Nuvalent in Pricing of US$500 Million Public Offering - Legal Desire Media and Insights
Jefferies raises Nuvalent stock price target to $164 on promising cancer drug data - Investing.com Nigeria
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC - The Malaysian Reserve
Can Nuvalent Inc. stock surprise with earnings upsideWeekly Trade Report & Safe Capital Growth Plans - newser.com
Will Nuvalent Inc. stock reach Wall Street targetsPortfolio Return Report & Accurate Buy Signal Notifications - newser.com
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment By Investing.com - Investing.com Nigeria
Nuvalent Insider Sold Shares Worth $2,065,030, According to a Recent SEC Filing - MarketScreener
Nuvalent Gets FDA Review of Zidesamtinib for ROS1-Positive Lung Cancer - MarketScreener
FDA accepts Nuvalent’s zidesamtinib application for lung cancer treatment - Investing.com
Nuvalent Executives Sell Over $4.6 Million in Stock - TradingView
Nuvalent Announces FDA Acceptance of New Drug Application for Zi - GuruFocus
CFO Balcom Sells 20,729 ($2.1M) Of Nuvalent Inc [NUVL] - TradingView
[Form 4] Nuvalent, Inc. Insider Trading Activity - Stock Titan
[424B5] Nuvalent, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Nuvalent announces FDA acceptance of new drug application for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC - MarketScreener
Can Nuvalent Inc. stock rebound after recent weaknessJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - newser.com
Nuvalent Announces Pricing of Public Offering of Common Stock - Eastern Progress
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Nuvalent (NUVL) - The Globe and Mail
Using economic indicators to assess Nuvalent Inc. potentialStock Surge & Free Technical Confirmation Trade Alerts - newser.com
What momentum indicators show for Nuvalent Inc. stockJuly 2025 Gainers & Safe Capital Growth Stock Tips - newser.com
Nuvalent Prices $500 Million Common Stock Offering - MarketScreener
0.22%
1.34%
大文字化:
|
ボリューム (24 時間):